We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

100 hedge funds and large institutions have $150M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $942K | Put options by funds: $314K

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

4% more funds holding

Funds holding: 96 → 100 (+4)

21% less capital invested

Capital invested by funds: $189M → $150M (-$39.4M)

Holders
100
Holders Change
+4
Holders Change %
+4.17%
% of All Funds
2.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
31
Reduced
28
Closed
8
Calls
$942K
Puts
$314K
Net Calls
+$628K
Net Calls Change
+$1.32M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.16M
2
AIM
ARK Investment Management
Florida
+$2.07M
3
JP Morgan Chase
JP Morgan Chase
New York
+$2.04M
4
FCM
Farallon Capital Management
California
+$925K
5
BCM
Bridgeway Capital Management
Texas
+$677K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$9.58M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.49M
3
Millennium Management
Millennium Management
New York
-$864K
4
Citadel Advisors
Citadel Advisors
Florida
-$709K
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$690K
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
76
Russell Investments Group
United Kingdom
$38K -$1.35K -20 -3%
Legal & General Group
77
Legal & General Group
United Kingdom
$37K – – –
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$29K -$49.6K -732 -61%
AIP
79
Ameritas Investment Partners
Nebraska
$27K – – –
Zurich Cantonal Bank
80
Zurich Cantonal Bank
Switzerland
$23K – – –
CG
81
Cutler Group
California
$20K – – –
IGGA
82
Iron Gate Global Advisors
Utah
$19K -$4.67K -69 -14%
TRCT
83
Tower Research Capital (TRC)
New York
$18K +$5.75K +85 +42%
LTFS
84
Ladenburg Thalmann Financial Services
Florida
$11K +$6.77K +100 +164%
KBC Group
85
KBC Group
Belgium
$10K – – –
CLOS
86
Compagnie Lombard Odier SCmA
Switzerland
$9K – – –
TC
87
Truvestments Capital
Florida
$7K +$7.79K +115 New
US Bancorp
88
US Bancorp
Minnesota
$6K – – –
SPIA
89
Steward Partners Investment Advisory
New York
$5K – – –
CAPTRUST Financial Advisors
90
CAPTRUST Financial Advisors
North Carolina
$4K – – –
SWM
91
SeaCrest Wealth Management
New York
$3K – – –
TWA
92
TCI Wealth Advisors
Arizona
$2K -$1.35K -20 -40%
APSP
93
Asset Planning Services (Pennsylvania)
Pennsylvania
$2K – – –
Bank of Montreal
94
Bank of Montreal
Ontario, Canada
$2K – – –
PMFA
95
Plante Moran Financial Advisors
Michigan
$2K – – –
WEC
96
Winslow Evans & Crocker
Massachusetts
$2K – – –
PCM
97
Prelude Capital Management
New York
$2K +$2.71K +40 New
Daiwa Securities Group
98
Daiwa Securities Group
Japan
$1K – – –
PCFFS
99
Pacific Center for Financial Services
California
$1K – – –
Walleye Trading
100
Walleye Trading
New York
$1K +$1.49K +22 New
1 2 3
4
5

BLCM Hedge Fund Activity: Q3 2018 in Review

100 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2018, worth a combined $150M — down 21% from $189M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BLCM positions and 8 closed out — a net gain of 4 holders — while 31 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $2.16M. The largest seller was Baker Bros. Advisors, cutting an estimated $9.58M.

  • 100 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2018, up from 96 in Q2 2018.
  • Funds reported $150M of Bellicum Pharmaceuticals, Inc. stock for Q3 2018, down 21% quarter-over-quarter.
  • 12 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2018 and 8 closed out, a net change of +4 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2018 was BlackRock, an estimated $2.16M added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2018 was Baker Bros. Advisors, an estimated $9.58M sold.

Based on aggregated 13F filings for Q3 2018.